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Introduction
In children, testicular tumors are uncommon, with an
incidence of approximately 0.5–2.0 per 100,000 indi-
viduals, and comprise about 1–2% of pediatric malig-
nancies.1–3 One study suggested that testicular tumors
may be more common in Asian than in Caucasian
children.4 However, only a few cases have been re-
ported in East Asia.2,5–7 To understand the differences
in the clinical manifestations and optimal management
of various prepubertal testicular tumors, we retrospec-
tively reviewed 34 children with testicular tumor over
the last 25 years at Taipei Veterans General Hospital
in Taipei, Taiwan.
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Background: Due to the rarity of testicular tumors in the prepubertal population, adequate information about their bio-
logical course is difficult to document well in a single institution. The purpose of this study was to focus on prepubertal
males in an attempt to evaluate clinical features and optimal management among various testicular germ cell tumors
with long-term follow-up.
Methods: We retrospectively reviewed the records of children younger than 12 years of age with primary testicular germ
cell tumors between February 1981 and December 2005 at Taipei Veterans General Hospital. Thirty-four children were
diagnosed with adequate clinical and pathologic data. The stage of the disease was determined according to the staging
system used by the Children’s Oncology Group. Mean follow-up time was 139 months (range, 2–283 months).
Results: All of the 34 prepubertal patients were diagnosed initially with a painless scrotal mass. The mean age of the
patients at diagnosis ranged from 6 months to 84 months (mean, 20.5 months). All patients underwent radical orchiec-
tomy as an initial treatment. Twenty-nine (85.3%) patients had yolk sac tumors, and 5 (14.7%) had mature teratomas. Of the
29 patients with yolk sac tumor, 26 (89.7%) were diagnosed as stage I, 1 (3.4%) as stage III, and 2 (7.0%) as stage IV.
Five (19.2%) of the 26 stage I yolk sac tumors progressed to metastasis after radical orchiectomy, and all of these 5
patients later received chemotherapy. One patient initially with stage III yolk sac tumor and 2 patients with stage IV yolk
sac tumor were also treated with chemotherapy. Eventually, 1 patient with stage IV yolk sac tumor died due to tumor pro-
gression; the remaining 28 patients with yolk sac tumor all survived without tumor relapse after appropriate treatment.
In the 5 patients with teratomas, there was no tumor relapse after radical orchiectomy with a mean follow-up time of
139.1 months. The 5-year survival rates for yolk sac tumor and teratomas were 96.5% and 100%, respectively.
Conclusion: The most common prepubertal malignant testicular tumor is yolk sac tumor, and the most common benign
testicular tumor is teratoma. Children with testicular germ cell tumors have excellent long-term survival rates after
appropriate treatment. [J Chin Med Assoc 2008;71(7):357–361]
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Methods
Between February 1981 and December 2005, 153
patients were diagnosed with testicular tumor in Taipei
Veterans General Hospital. Children younger than 12
years of age with adequate clinical and pathologic
data were evaluated. Tumor review criteria included
patient age at diagnosis, presentation, radiologic inves-
tigation and tumor markers. All patients presented
with a palpable scrotal mass and underwent radical
orchiectomy via an inguinal approach as initial treat-
ment. The disease stage was determined according to
the staging system used by the Children’s Oncology
Group:8 stage I, tumor limited to the testes; stage II,
microscopic residual tumor or persistent elevated
tumor markers after complete orchiectomy; stage III,
tumor metastasis to retroperitoneal lymph nodes and
size < 4 cm; and stage IV, tumor metastasis to a site
other than the retroperitoneal lymph nodes or retro-
peritoneal lymph nodes ≥ 4 cm. Relapse was defined
as increasing serum tumor markers, or the appearance
of radiographic evidence of disease during follow-up.
Over the 25-year period, the treatment of patients
differed depending on the time of diagnosis. As shown
in Figure 1, 4 patients with testicular stage I yolk sac
tumors diagnosed before 1983 received adjuvant che-
motherapy with actinomycin D monthly for 1 year after
radical inguinal orchiectomy. The remaining 22 patients
with stage I yolk sac tumor diagnosed after 1983
received radical orchiectomy only. The only stage III
patient and 1 of 2 stage IV patients were treated with
cisplatin, vinblastine and bleomycin (PVB). The other
patient with stage IV yolk sac tumor with lung metas-
tasis at diagnosis received chemotherapy with cyclo-
phosphamide, actinomycin D and methotrexate.
Outcome data including tumor histopathology,
evidence of metastases, treatment modalities and sur-
vival were included. Statistical analyses were performed
using the Kaplan-Meyer method. A probability level
of p < 0.05 was taken as statistically significant.
Results
Between February 1981 and December 2005, there
were 34 children (age < 12 years) who were diagnosed
with testicular tumors, and they were enrolled in the
study. Twenty-nine yolk sac tumors and 5 teratomas
in the children were reviewed. The mean prepubertal
patient ages at diagnosis were 19.8 months (range,
6–47 months) and 24.9 months (range, 6–84 months)
for yolk sac tumors and teratomas, respectively. All 34
patients were followed-up from 2 to 283 months, with
a mean of 139 months after treatment.
For the children with yolk sac tumor, all 29 had ele-
vation of serum alpha-fetoprotein (AFP) at diagnosis.
Serial preoperative AFP ranged from 60 to 66,641
ng/mL, with a mean of 6,537 ng/mL. As shown in
Figure 1, there were 2 stage IV children who had lung
metastasis at diagnosis. One died of progressive metas-
tasis 2 months later despite chemotherapy. The other
survived without relapse for 112 months after radical
orchiectomy and chemotherapy with PVB. Addition-
ally, 1 stage III child who had enlarged retroperitoneal
lymph node survived without relapse for 15 years
after radical orchiectomy and chemotherapy with PVB.
For 26 children with stage I disease, 4 children who
underwent adjuvant chemotherapy with actinomycin
D had no tumor relapse with regular follow-up. Five
of the remaining 22 stage I (19.2%) children with
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Figure 1. Yolk sac tumors with various stages. C/T = chemotherapy; PVB = cisplatin, vinblastine and bleomycin.
stage I yolk sac tumor had recurrence with elevated
AFP after the treatment of radical inguinal orchiec-
tomy only. Then, chest radiograph or chest/abdomi-
nal computed tomography were performed. As shown
in Figure 2, 2 patients with tumor recurrence in the
lung were diagnosed 9 months and 11 months later,
respectively, and the other 3 experienced recurrence
over the retroperitoneum 3, 7 and 25 months post-
orchiectomy, respectively. These 5 children with tumor
relapse received cisplatin-based combination chemo-
therapy. Additionally, 2 of 3 patients with retroperito-
neal lymph node metastasis underwent retroperitoneal
lymph node dissection for residue mass after 6 cycles
of chemotherapy. These 5 children with tumor recur-
rence after radical orchiectomy were all alive without
relapse, and the mean follow-up was 212.6 months
(range, 175.8–255.6 months).
In the 5 patients with teratomas, all pathologic re-
ports were of stage I mature teratomas. Neither tumor
recurrence nor distant metastasis was noted during
follow-up. The 5-year survival rates for yolk sac tumors
and teratomas were 96.5% and 100%, respectively.
Discussion
Testicular tumors in the prepubertal population are
fundamentally distinct from those in the adult popu-
lation. Adult testicular tumors are frequently comprised
of a mixed histology, and they are often malignant.9
In contrast, prepubertal testicular tumors typically con-
tain only 1 histologic type, and they are either benign
or malignant equally.10–13 In our series, 14% (5/34)
of prepubertal testicular tumors were benign testicu-
lar teratoma. The other 86% (29/34) of prepubertal
testicular tumors were malignant and contained only
1 histologic type of yolk sac tumor.
Due to the rarity of prepubertal testicular tumors,
the Section of Urology of the American Academy of
Pediatrics (AAP) prompted the creation of the Prepu-
bertal Testicular Tumor Registry (PTTR) in 1980, and
Ross et al reported their most recent data on the demo-
graphics and natural history of prepubertal testis tumors
in 2002.14 In the PTTR, the most common prepuber-
tal testicular tumors were yolk sac tumors, and the sec-
ond most common were teratomas. There were some
reviews of prepubertal testicular tumors in East Asia
(Table 1). Two long-term reviews for 30 and 27 years,
respectively, from 2 Japan medical centers revealed that
the most common prepubertal testicular tumors were
yolk sac tumors.5,6 Additionally, there were 25 prepu-
bertal yolk sac tumors and 24 mature teratomas in
Beijing Children’s Attached Hospital of Capital Medical
University.7 The largest multi-institutional report on
prepubertal testicular tumors in Asia is from Korea.2
There, 100 yolk sac tumors and 83 teratomas were
recorded. In all of the above reports, the results were
consistent with our report. The most common type
of malignant tumor was yolk sac tumor, and the most
common type of benign tumor was mature teratoma.
In yolk sac tumors, the epithelial lining of the cysts
and tubules is the site of synthesis of AFP. So yolk sac
tumors frequently secrete high concentrations of se-
rum AFP, which is considered important in the diag-
nosis and follow-up of the tumors.15,16 AFP is the fetal
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Figure 2. Stage I yolk sac tumor with recurrence. C/T =
chemotherapy; mets = metastasis; RPLN = retroperitoneal lymph
node; RPLND = retroperitoneal lymph node dissection.
Table 1. The incidence of prepubertal germ cell testicular tumors
Country Yolk sac tumor Teratoma Epidermal cyst Other germ cell tumors
Ross et al14 USA 244 92 13 0
Kanto et al6 Japan 10 3 1 0
Terai et al5 Japan 7 5 0 0
Lee2 Korea 100 83 6 6 (mixed germ cell)
Song & Huang7 China 25 24 2 1 (seminoma)
This study Taiwan 29 5 0 0
Total 415 212 22 7
albumin equivalent, and it is also produced by fetal he-
patocytes. The concentration of AFP remains increased
in all newborns until the age of 8 months (0–20 ng/
mL), so serum AFP cannot be used to distinguish a yolk
sac neoplasm from other testicular pathologies during
this early period of life. However, increased AFP was
reported in 94.7% of yolk sac tumors and 30.4% of
teratomas.2 But none of our teratoma patients aged
6–12 months old had AFP levels > 100 ng/mL. These
data suggest that infants younger than 1 year with
AFP > 100 ng/mL should be presumed to have a yolk
sac tumor. In most cases, serum AFP levels can be mon-
itored postoperatively to reliably indicate testicular
tumor recurrence during follow-up.17,18 If AFP levels
do not decrease by the 5-day half-life after radical orchi-
ectomy, residual tumor or metastatic disease should
be considered. In our study, rising AFP concentrations
were found in 5 children with tumor recurrence and
correlated with the time of recurrence. Serum tumor
markers play an important role in distinguishing among
the different histologic types before surgery, and they
are used to detect tumor recurrence or residual tumors
after radical inguinal orchiectomy.
For stage I disease, active surveillance after radical
orchiectomy can be followed without the need for
adjuvant chemotherapy.19 However, 10–25% of patients
who received radical orchiectomy alone had a later
relapse and subsequently died.20,21
Therefore, Liu et al22 suggested that 2 or 3 courses
of chemotherapy with PVB after radical orchiectomy
for stage I prepubertal yolk sac tumor of the testis in
children younger than 2 years was more effective com-
pared with the standard treatment of radical orchiec-
tomy alone.
A number of different cisplatin-based chemotherapy
regimens, such as PVB and PEB (bleomycin, etoposide,
cisplatin), have been used by the UK Children’s Cancer
Study Group. Many studies reported that, with current
chemotherapy protocols, not only can all recurrences
and metastasis be salvaged with platinum-based multi-
agent chemotherapy,23 but survival rates for all disease
stages approach 100%, and there is less morbidity.17
In some studies, metastasis from yolk sac tumors
in children are more likely to occur to the lung (20%)
than to the retroperitoneum (4–6%).17,19 Routine
retroperitoneal lymph node dissection (RPLND) is ex-
cluded for the treatment of pediatric stage I yolk sac
tumor, and many metastatic lymph nodes may be
remitted after chemotherapy. The relapse-free survival
rate of stage I yolk sac tumor was not improved after
routine lymphadenectomy.24 In our series, only 1 stage
III yolk sac tumor (3.4%) and 3 relapsed stage I yolk
sac tumors (10.3%) had retroperitoneal lymph node
metastasis. But the enlarged retroperitoneal lymph
nodes in the patient with stage III tumor and 1 relapsed
stage I patient were alleviated after chemotherapy, and
RPLND was a needless operation in these patients.
So, RPLND is not a routine operation for patients
with retroperitoneal masses after chemotherapy.
Teratomas without pubertal change are uniformly
benign in prepubertal testes.25 As a result of their
benign nature, testis-sparing surgery has evolved from
radical orchiectomy due to there being no tumor re-
currence with long-term follow-up.12,26 In our study,
preoperative diagnosis of teratomas could not be dif-
ferentiated from malignancy. All 5 cases received radical
orchiectomy. In teratoma, frozen section is an impor-
tant practice to confirm the diagnosis of benign or ma-
lignant tumor and ensure complete tumor removal.
Frozen section can also assess the adjacent testicular
parenchyma to determine whether or not there are pu-
bertal changes. A teratoma with presence of pubertal
changes by frozen section is considered to be malignant.
So radical orchiectomy and surveillance protocols sim-
ilar to those performed in adult patients with teratomas
are necessary as teratomas can be malignant in puber-
tal children.27 Because of the extremely low incidence
of multifocal disease and there being no discordance
between frozen section and definitive histopathology
in several series, testis-sparing surgery is considered
safe for teratomas without pubertal change.28,29
In conclusion, of all prepubertal testicular tumors,
the most common malignant tumor is yolk sac tumor,
and the most common benign tumor is mature terato-
ma. Serum AFP is a useful tumor marker to distinguish
different histologic types before surgery and to detect
tumor recurrence or residual tumors after radical in-
guinal orchiectomy. Most of the patients in this study
with distal metastasis or tumor relapse survived without
disease after cisplatin-based combination chemotherapy.
Teratomas without pubertal change are uniformly be-
nign, and they do not require further radiographic
follow-up for local or metastatic recurrence after radi-
cal orchiectomy. Due to the small number of testicular
tumor cases, a multi-institutional report on prepubertal
testicular tumors with long-term follow-up is necessary.
References
1. Brosman SA. Testicular tumors in prepubertal children.
Urology 1979;13:581–8.
2. Lee SD. Epidemiological and clinical behavior of prepubertal
testicular tumors in Korea. J Urol 2004;172:674–8.
3. Kaplan GW, Cromie WC, Kelalis PP, Silber I, Tank ES Jr.
Prepubertal yolk sac testicular tumors—report of the testicular
tumor registry. J Urol 1988;140:1109–12.
J Chin Med Assoc • July 2008 • Vol 71 • No 7360
Y.S. Chen, et al
4. Karamehmedovic O, Woodtli W, Pluss HJ. Testicular tumors in
childhood. J Pediatr Surg 1975;10:109–14.
5. Terai A, Kawakita M, Yoshida O. Clinical experience with 
yolk sac tumors and teratoma in children. Int J Urol 1994;1:
167–71.
6. Kanto S, Saito H, Ito A, Satoh M, Saito S, Arai Y. Clinical features
of testicular tumors in children. Int J Urol 2004;11:890–3.
7. Song HC, Huang CR. Testicular tumors in children (report of
55 cases). Chi J Urol 2004;25:44–6.
8. Ritchey ML, Shamberger RC. Pediatric urologic oncology. In:
Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, eds.
Campbell’s Urology, 9th edition. Philadelphia: Saunders, 2007:
3900–5.
9. Reuter VE. Origins and molecular biology of testicular germ
cell tumors. Mod Pathol 2005;18:S51–60.
10. Leonard MP, Jeffs RD, Leventhal B, Gearhart JP. Pediatric tes-
ticular tumors: the Johns Hopkins experience. Urology 1991;
37:253–6.
11. Kay R. Prepubertal testicular tumor registry. Urol Clin North
Am 1993;20:1–5.
12. Sugita Y, Clarnette TD, Cooke-Yarborough C, Chow CW,
Waters K, Hutson JM. Testicular and paratesticular tumours in
children: 30 years’ experience. Aust N Z J Surg 1999;69:
505–8.
13. Green DM. Testicular tumors in infants and children. Semin
Surg Oncol 1986;2:156–62.
14. Ross JH, Rybicki L, Kay R. Clinical behavior and a contempo-
rary management algorithm for prepubertal testis tumors: a
summary of the Prepubertal Testis Tumor Registry. J Urol
2002;168:1675–8.
15. Homsy Y, Arrojo-Vila F, Khoriaty N, Demers J. Yolk sac tumor
of the testicle: is retroperitoneal lymph node dissection neces-
sary? J Urol 1984;132:532–6.
16. Talerman A, Haije WG, Baggerman L. Serum alphafetoprotein
(AFP) in patients with germ cell tumors of the gonads and
extragonadal sites: correlation between endodermal sinus (yolk
sac) tumor and raised serum AFP. Cancer 1980;46:380–5.
17. Grady RW, Ross JH, Kay R. Patterns of metastatic spread in
prepubertal yolk sac tumor of the testis. J Urol 1995;153:
1259–61.
18. Weissbach L, Altwein JE, Stiens R. Germinal testicular tumors
in childhood. Report of observations and literature review. Eur
Urol 1984;10:73–85.
19. Drago JR, Nelson RP, Palmer JM. Childhood embryonal car-
cinoma of testes. Urology 1978;12:499–503.
20. Hopkins TB, Jaffe N, Colodny A, Cassady JR, Filler RM. The
management of testicular tumors in children. J Urol 1978;120:
96–102.
21. Green DM. The diagnosis and treatment of yolk sac tumors in
infants and children. Cancer Treat Rev 1983;10:265–88.
22. Liu HC, Liang DC, Chen SH, Liu FL, Chang PY, Sheu JC,
Wang NL. The stage I yolk sac tumor of testis in children
younger than 2 years, chemotherapy or not? Pediatr Hematol
Oncol 1998;15:223–8.
23. Haas RJ, Schmidt P, Gobel U, Harms D. Treatment of malignant
testicular tumors in childhood: results of the German National
Study 1982–1992. Med Pediatr Oncol 1994;23:400–5.
24. Kaplan WE, Firlit CF. Treatment of testicular yolk sac carci-
noma in the young child. J Urol 1981;126:663–4.
25. Grady RW, Ross JH, Kay R. Epidemiological features of testic-
ular teratoma in a prepubertal population. J Urol 1997;
158:1191–2.
26. Ross JH, Kay R, Elder J. Testis sparing surgery for pediatric
epidermoid cysts of the testis. J Urol 1993;149:353–6.
27. Ross JH, Kay R. Prepubertal testis tumors. Rev Urol 2004;
6:11–8.
28. Tokuc R, Sakr W, Pontes JE, Haas GP. Accuracy of frozen sec-
tion examination of testicular tumors. Urology 1992;40:512–6.
29. Valla JS. Testis-sparing surgery for benign testicular tumors in
children. J Urol 2001;165:2280–3.
J Chin Med Assoc • July 2008 • Vol 71 • No 7 361
Prepubertal testicular germ cell tumors
